HRP20230070T1 - Tasimelteon za liječenje smith-magenis sindroma - Google Patents
Tasimelteon za liječenje smith-magenis sindroma Download PDFInfo
- Publication number
- HRP20230070T1 HRP20230070T1 HRP20230070TT HRP20230070T HRP20230070T1 HR P20230070 T1 HRP20230070 T1 HR P20230070T1 HR P20230070T T HRP20230070T T HR P20230070TT HR P20230070 T HRP20230070 T HR P20230070T HR P20230070 T1 HRP20230070 T1 HR P20230070T1
- Authority
- HR
- Croatia
- Prior art keywords
- tasimelteon
- use according
- sleep
- improvement
- treatment
- Prior art date
Links
- PTOIAAWZLUQTIO-GXFFZTMASA-N tasimelteon Chemical compound CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2 PTOIAAWZLUQTIO-GXFFZTMASA-N 0.000 title claims 18
- 229960000660 tasimelteon Drugs 0.000 title claims 18
- 201000001388 Smith-Magenis syndrome Diseases 0.000 title claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 230000000422 nocturnal effect Effects 0.000 claims 2
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000002618 waking effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electric Connection Of Electric Components To Printed Circuits (AREA)
- Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Processing Of Solid Wastes (AREA)
- Steroid Compounds (AREA)
- Coils Or Transformers For Communication (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Claims (10)
1. Tasimelteon za upotrebu u liječenju poremećaja spavanja kod pacijenata sa Smith-Magenisovim sindromom (SMS), takvo liječenje uključuje dnevnu internu primjenu pacijentu učinkovite količine tasimelteona prije spavanja.
2. Tasimelteon za upotrebu prema zahtjevu 1, naznačen time što se liječenje poremećaja spavanja očituje kao poboljšanje noćnog sna.
3. Tasimelteon za upotrebu prema zahtjevu 2, naznačen time što se poboljšanje noćnog sna očituje kao smanjenje postotka perioda budnosti unutar intervala spavanja pacijenta.
4. Tasimelteon za upotrebu prema zahtjevu 1, naznačen time što se liječenje poremećaja spavanja očituje kao poboljšanje jednog ili više od sljedećeg: ukupne količine noćnog sna; broja, vremena i duljine noćnih buđenja; početka sna; vremena buđenja; broja, vremena i duljine dnevnih drijemanja; poboljšanje kliničkog globalnog dojma promjene (CGI-C); poboljšanje kliničkog globalnog dojma ozbiljnosti (CGI-S); i poboljšanje ponašanja.
5. Tasimelteon za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time što se tasimelteon primjenjuje jednom dnevno.
6. Tasimelteon za upotrebu prema zahtjevu 5, naznačen time što je doza tasimelteona između oko 5 mg/dan i oko 100 mg/dan.
7. Tasimelteon za upotrebu prema zahtjevu 6, naznačen time što je doza tasimelteona oko 20 mg/dan.
8. Tasimelteon za upotrebu prema zahtjevu 1, naznačen time što se tasimelteon primjenjuje između pola sata i dva sata prije spavanja.
9. Tasimelteon za upotrebu prema zahtjevu 8, naznačen time što se tasimelteon primjenjuje između pola sata i jedan i pol sata prije spavanja.
10. Tasimelteon za upotrebu prema zahtjevu 9, naznačen time što se tasimelteon daje jedan sat prije spavanja.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462044856P | 2014-09-02 | 2014-09-02 | |
| US201562169635P | 2015-06-02 | 2015-06-02 | |
| PCT/US2015/047610 WO2016036619A1 (en) | 2014-09-02 | 2015-08-29 | Tasimelteon for treating smith-magenis syndrome |
| EP15766274.3A EP3188727B1 (en) | 2014-09-02 | 2015-08-29 | Tasimelteon for treating smith-magenis syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230070T1 true HRP20230070T1 (hr) | 2023-03-17 |
Family
ID=54147267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230070TT HRP20230070T1 (hr) | 2014-09-02 | 2015-08-29 | Tasimelteon za liječenje smith-magenis sindroma |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10179119B2 (hr) |
| EP (2) | EP4137129A1 (hr) |
| JP (3) | JP6903571B2 (hr) |
| KR (2) | KR20240015729A (hr) |
| CN (2) | CN116098887A (hr) |
| AU (2) | AU2015312252B2 (hr) |
| BR (1) | BR112017003644A2 (hr) |
| CA (2) | CA2957588C (hr) |
| DK (1) | DK3188727T3 (hr) |
| ES (1) | ES2936833T3 (hr) |
| FI (1) | FI3188727T3 (hr) |
| HR (1) | HRP20230070T1 (hr) |
| HU (1) | HUE061051T2 (hr) |
| MX (1) | MX2017002796A (hr) |
| PT (1) | PT3188727T (hr) |
| SI (1) | SI3188727T1 (hr) |
| WO (1) | WO2016036619A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4137129A1 (en) * | 2014-09-02 | 2023-02-22 | Vanda Pharmaceuticals Inc. | Tasimelteon for treating smith-magenis syndrome |
| CN112074268A (zh) * | 2018-03-04 | 2020-12-11 | 万达制药公司 | 用他司美琼治疗疾病 |
| JP2022500420A (ja) * | 2018-09-12 | 2022-01-04 | バンダ・ファーマシューティカルズ・インコーポレイテッドVanda Pharmaceuticals Inc. | 睡眠又は睡眠後パフォーマンスの改善 |
| JP2023506225A (ja) | 2019-12-13 | 2023-02-15 | バンダ・ファーマシューティカルズ・インコーポレイテッド | 液体タシメルテオン製剤及びそれを使用する方法 |
| JPWO2022044826A1 (hr) | 2020-08-27 | 2022-03-03 | ||
| AU2022345260A1 (en) * | 2021-09-14 | 2024-04-04 | Vanda Pharmaceuticals Inc. | Treatment of sleep disturbances in autism spectrum disorder patients |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1027043E (pt) | 1996-12-10 | 2005-02-28 | Bristol Myers Squibb Co | Benzodioxole benzofurano di-hidrobenzofurano e benzodioxano como agentes melatonergicos |
| WO2005063240A1 (en) | 2003-12-22 | 2005-07-14 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
| US7754902B2 (en) | 2006-05-18 | 2010-07-13 | Vanda Pharmaceuticals, Inc. | Ruthenium(II) catalysts for use in stereoselective cyclopropanations |
| JP2009538332A (ja) | 2006-05-22 | 2009-11-05 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | メラトニンアゴニスト治療 |
| US20080260837A1 (en) | 2007-04-20 | 2008-10-23 | Qpharma, L.L.C. | Physically stable aqueous suspensions of active pharmaceuticals |
| KR100928515B1 (ko) | 2008-04-02 | 2009-11-26 | 주식회사 동부하이텍 | 데이터 수신 장치 |
| US20120136050A1 (en) | 2009-07-16 | 2012-05-31 | Vanda Pharmaceuticals Inc. | Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia |
| ES2646197T3 (es) | 2012-01-26 | 2017-12-12 | Vanda Pharmaceuticals Inc. | Tratamiento de trastornos del ritmo circadiano |
| CN102675268A (zh) * | 2012-05-18 | 2012-09-19 | 济南志合医药科技有限公司 | 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法 |
| US10376487B2 (en) * | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| EP4137129A1 (en) * | 2014-09-02 | 2023-02-22 | Vanda Pharmaceuticals Inc. | Tasimelteon for treating smith-magenis syndrome |
| JP2023506225A (ja) * | 2019-12-13 | 2023-02-15 | バンダ・ファーマシューティカルズ・インコーポレイテッド | 液体タシメルテオン製剤及びそれを使用する方法 |
-
2015
- 2015-08-29 EP EP22199492.4A patent/EP4137129A1/en active Pending
- 2015-08-29 JP JP2017512287A patent/JP6903571B2/ja active Active
- 2015-08-29 PT PT157662743T patent/PT3188727T/pt unknown
- 2015-08-29 CN CN202310255914.1A patent/CN116098887A/zh active Pending
- 2015-08-29 DK DK15766274.3T patent/DK3188727T3/da active
- 2015-08-29 CA CA2957588A patent/CA2957588C/en active Active
- 2015-08-29 AU AU2015312252A patent/AU2015312252B2/en active Active
- 2015-08-29 KR KR1020247002426A patent/KR20240015729A/ko active Search and Examination
- 2015-08-29 MX MX2017002796A patent/MX2017002796A/es unknown
- 2015-08-29 BR BR112017003644A patent/BR112017003644A2/pt not_active Application Discontinuation
- 2015-08-29 SI SI201531919T patent/SI3188727T1/sl unknown
- 2015-08-29 CN CN201580046852.7A patent/CN106604726A/zh active Pending
- 2015-08-29 CA CA3124872A patent/CA3124872A1/en active Pending
- 2015-08-29 HU HUE15766274A patent/HUE061051T2/hu unknown
- 2015-08-29 EP EP15766274.3A patent/EP3188727B1/en active Active
- 2015-08-29 ES ES15766274T patent/ES2936833T3/es active Active
- 2015-08-29 FI FIEP15766274.3T patent/FI3188727T3/fi active
- 2015-08-29 US US15/326,934 patent/US10179119B2/en active Active
- 2015-08-29 HR HRP20230070TT patent/HRP20230070T1/hr unknown
- 2015-08-29 WO PCT/US2015/047610 patent/WO2016036619A1/en active Application Filing
- 2015-08-29 KR KR1020177009052A patent/KR20170048541A/ko active Application Filing
-
2018
- 2018-12-06 US US16/211,687 patent/US10653665B2/en active Active
-
2020
- 2020-04-14 US US16/848,150 patent/US11266622B2/en active Active
- 2020-06-04 JP JP2020097599A patent/JP7132277B2/ja active Active
- 2020-09-22 AU AU2020239640A patent/AU2020239640B2/en active Active
-
2022
- 2022-01-14 US US17/648,046 patent/US20220133681A1/en active Pending
- 2022-03-14 JP JP2022039475A patent/JP7252390B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230070T1 (hr) | Tasimelteon za liječenje smith-magenis sindroma | |
| HRP20211314T1 (hr) | 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu uporabu | |
| MX355065B (es) | Método y dispositivo para conmutación de cámaras. | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2014111603A5 (hr) | ||
| HRP20201069T1 (hr) | Primjena tasimelteona pod uvjetima natašte | |
| EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| BR112015029484A2 (pt) | dispositivo de avanço mandibular ajustável incremental para prevenção e tratamento de ronco e apneia obstrutiva do sono | |
| JP2015057451A5 (hr) | ||
| JP2015534562A5 (hr) | ||
| UY37328A (es) | Compuestos diazaheterobicíclicos sustituidos y su uso | |
| EA201170018A1 (ru) | Разагилин для изменения течения болезни паркинсона | |
| BR112014032699A2 (pt) | métodos de tratamento de síndrome metabólica pediátrica | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| WO2014058979A3 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| CU20190060A7 (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 útiles en el tratamiento de trastornos respiratorios | |
| JP2017526693A5 (hr) | ||
| JP2016530291A5 (hr) | ||
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| PL405125A1 (pl) | Cząsteczka miR172 pochodzenia roślinnego lub jej syntetyczny ekwiwalent, sposób zmniejszania proliferacji limfocytów B oraz zastosowanie cząsteczki miR172 | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| JP2016535794A5 (ja) | 急速崩壊性固体剤形 |